PDGFRB and acute lymphoblastic leukemia: Imatinib is a first generation TKI approved for the treatment of CML and Philadelphia-positive acute lymphoblastic leukemia (ALL) and for myelodysplastic/myeloproliferative diseases carrying the PDGFR rearrangement.